Pasar al contenido principal

FUNCION DEL METABOLISMO DEL GLUCOGENO EN EL TEJIDO ADIPOSO: INVESTIGACION TRANSLACIONAL PARA LA BUSQUEDA DE NUEVAS DIANAS TERAPEUTICAS EN EL TRATAMIENTO DE LA OBESIDAD

SAF2012-36186

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2012
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Secretaría de Estado de Investigación, Desarrollo e Innovación
Centro beneficiario FUNDACIO INSTITUT D'INVESTIGACIO SANITARIA PERE VIRGILI
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

FGF-23/vitamin D axis in type 1 diabetes: the potential role of mineral metabolism in arterial stiffness.

  • Llauradó Cabot, Gemma
  • Megia, Ana
  • Cano, Albert
  • Giménez Palop, Olga
  • Simón, Inmaculada
  • González Sastre, Montserrat
  • Berlanga, Eugenio
  • Fernández Veledo, Sonia
  • Vendrell, Joan
  • González Clemente, José Miguel
OBJECTIVE: To investigate the usefulness of Fibroblast Growth Factor 23 (FGF-23) and vitamin D as possible biomarkers of pre-clinical atherosclerosis, assessed as arterial stiffness (AS), in a group of subjects with type 1 diabetes (T1DM) and no previous cardiovascular events. RESEARCH DESIGN AND METHODS: 68 T1DM patients and 68 age- and sex-matched controls were evaluated for 1) age, sex, diabetes duration, physical activity, smoking, alcohol intake, BMI, blood pressure, fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR) and lipid profile; 2) microvascular complications; 3) blood concentrations of FGF-23 and mineral metabolism parameters (calcium, phosphate, parathyroid hormone (PTH) and 25-hydroxy-vitamin D (25(OH)D)); 4) AS, assessed as aortic pulse wave velocity (aPWV); and 5) low-grade inflammation (hsCRP, IL-6, sTNFαR1, sTNFαR2) and endothelial dysfunction (ED) markers (ICAM-1, VCAM-1, E-Selectin). RESULTS: Patients with T1DM had higher aPWV compared with controls (p<0.001), but they did not present differences in 25(OH)D (70.3(50.4-86.2)nmol/L vs. 70.7(59.7-83.0)nmol/L; p = 0.462) and in FGF-23 plasma concentrations (70.1(38.4-151.9)RU/mL vs. 77.6(51.8-113.9)RU/mL; p = 0.329). In T1DM patients, higher concentrations of FGF-23 were positively associated with aPWV after adjusting for eGFR and classical cardiovascular risk factors (model 1: ß = 0.202, p = 0.026), other mineral metabolism parameters (model 2: ß = 0.214, p = 0.015), microvascular complications, low-grade inflammation and ED markers (model 3: ß = 0.170, p = 0.045). Lower 25(OH)D concentrations were also associated with higher aPWV after adjusting for all the above-mentioned factors (model 3: ß = -0.241, p = 0.015). CONCLUSIONS: We conclude that both FGF-23 plasma concentrations (positively) and 25(OH)D serum concentrations (negatively) are associated with AS in patients with T1DM and no previous cardiovascular events., Financial support was provided by a grant from the Fondo de Investigación Sanitaria (FIS) (PS09/01360 and PI12/00954) by Instituto de Salud Carlos III (Spain) and the Fundació La Marató de TV3-2008 (Project N° 081410). The study was also cofunded by Fondos FEDER and CIBER de Diabetes y Enfermedades Metabólicas asociadas CIBERDEM (CB07/08/0012), SAF2012-36186 and CP10/00438 to SF-V (Spanish Ministry of Economy and Competitiveness). CIBERDEM de Diabetes y Enfermedades Metabólicas asociadas (CB07708/ 0012) is an initiative of the Instituto de Salud Carlos III. GL was supported by a “Rio Hortega” research fellowship (CM12/00044) from the Instituto de Salud Carlos III (Spain). SF-V acknowledges support from the "Miguel Servet" tenure track program (CP10/ 00438), from the Fondo de Investigación Sanitaria (FIS), co-financed by the European Regional Development Fund (ERDF).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

FGF-23/vitamin D axis in type 1 diabetes: the potential role of mineral metabolism in arterial stiffness.

  • Llauradó Cabot, Gemma
  • Megia, Ana
  • Cano, Albert
  • Giménez Palop, Olga
  • Simón, Inmaculada
  • González Sastre, Montserrat
  • Berlanga, Eugenio
  • Fernández Veledo, Sonia
  • Vendrell, Joan
  • González Clemente, José Miguel
OBJECTIVE: To investigate the usefulness of Fibroblast Growth Factor 23 (FGF-23) and vitamin D as possible biomarkers of pre-clinical atherosclerosis, assessed as arterial stiffness (AS), in a group of subjects with type 1 diabetes (T1DM) and no previous cardiovascular events. RESEARCH DESIGN AND METHODS: 68 T1DM patients and 68 age- and sex-matched controls were evaluated for 1) age, sex, diabetes duration, physical activity, smoking, alcohol intake, BMI, blood pressure, fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR) and lipid profile; 2) microvascular complications; 3) blood concentrations of FGF-23 and mineral metabolism parameters (calcium, phosphate, parathyroid hormone (PTH) and 25-hydroxy-vitamin D (25(OH)D)); 4) AS, assessed as aortic pulse wave velocity (aPWV); and 5) low-grade inflammation (hsCRP, IL-6, sTNFαR1, sTNFαR2) and endothelial dysfunction (ED) markers (ICAM-1, VCAM-1, E-Selectin). RESULTS: Patients with T1DM had higher aPWV compared with controls (p<0.001), but they did not present differences in 25(OH)D (70.3(50.4-86.2)nmol/L vs. 70.7(59.7-83.0)nmol/L; p = 0.462) and in FGF-23 plasma concentrations (70.1(38.4-151.9)RU/mL vs. 77.6(51.8-113.9)RU/mL; p = 0.329). In T1DM patients, higher concentrations of FGF-23 were positively associated with aPWV after adjusting for eGFR and classical cardiovascular risk factors (model 1: ß = 0.202, p = 0.026), other mineral metabolism parameters (model 2: ß = 0.214, p = 0.015), microvascular complications, low-grade inflammation and ED markers (model 3: ß = 0.170, p = 0.045). Lower 25(OH)D concentrations were also associated with higher aPWV after adjusting for all the above-mentioned factors (model 3: ß = -0.241, p = 0.015). CONCLUSIONS: We conclude that both FGF-23 plasma concentrations (positively) and 25(OH)D serum concentrations (negatively) are associated with AS in patients with T1DM and no previous cardiovascular events., Financial support was provided by a grant from the Fondo de Investigación Sanitaria (FIS) (PS09/01360 and PI12/00954) by Instituto de Salud Carlos III (Spain) and the Fundació La Marató de TV3-2008 (Project N° 081410). The study was also cofunded by Fondos FEDER and CIBER de Diabetes y Enfermedades Metabólicas asociadas CIBERDEM (CB07/08/0012), SAF2012-36186 and CP10/00438 to SF-V (Spanish Ministry of Economy and Competitiveness). CIBERDEM de Diabetes y Enfermedades Metabólicas asociadas (CB07708/ 0012) is an initiative of the Instituto de Salud Carlos III. GL was supported by a “Rio Hortega” research fellowship (CM12/00044) from the Instituto de Salud Carlos III (Spain). SF-V acknowledges support from the "Miguel Servet" tenure track program (CP10/ 00438), from the Fondo de Investigación Sanitaria (FIS), co-financed by the European Regional Development Fund (ERDF).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

FGF-23/Vitamin D Axis in Type 1 Diabetes, The Potential Role of Mineral Metabolism in Arterial Stiffness

  • Llauradó, Gemma|||0000-0002-3237-6366
  • Megía, Ana|||0000-0002-5101-9452
  • Cano, Albert|||0000-0002-2804-3745
  • Giménez-Palop, Olga|||0000-0002-4526-6342
  • Simón, Inmaculada
  • González-Sastre, Montserrat
  • Berlanga Escalera, Eugenio|||0000-0002-9774-4051
  • Fernández-Veledo, Sonia|||0000-0003-2906-3788
  • Vendrell, Joan|||0000-0002-6994-6115
  • González Clemente, José Miguel|||0000-0002-7409-8720
To investigate the usefulness of Fibroblast Growth Factor 23 (FGF-23) and vitamin D as possible biomarkers of pre-clinical atherosclerosis, assessed as arterial stiffness (AS), in a group of subjects with type 1 diabetes (T1DM) and no previous cardiovascular events. 68 T1DM patients and 68 age- and sex-matched controls were evaluated for 1) age, sex, diabetes duration, physical activity, smoking, alcohol intake, BMI, blood pressure, fasting plasma glucose, HbA, estimated glomerular filtration rate (eGFR) and lipid profile; 2) microvascular complications; 3) blood concentrations of FGF-23 and mineral metabolism parameters (calcium, phosphate, parathyroid hormone (PTH) and 25-hydroxy-vitamin D (25(OH)D)); 4) AS, assessed as aortic pulse wave velocity (aPWV); and 5) low-grade inflammation (hsCRP, IL-6, sTNFαR1, sTNFαR2) and endothelial dysfunction (ED) markers (ICAM-1, VCAM-1, E-Selectin). Patients with T1DM had higher aPWV compared with controls (p<0.001), but they did not present differences in 25(OH)D (70.3(50.4-86.2)nmol/L vs. 70.7(59.7-83.0)nmol/L; p = 0.462) and in FGF-23 plasma concentrations (70.1(38.4-151.9)RU/mL vs. 77.6(51.8-113.9)RU/mL; p = 0.329). In T1DM patients, higher concentrations of FGF-23 were positively associated with aPWV after adjusting for eGFR and classical cardiovascular risk factors (model 1: ß = 0.202, p = 0.026), other mineral metabolism parameters (model 2: ß = 0.214, p = 0.015), microvascular complications, low-grade inflammation and ED markers (model 3: ß = 0.170, p = 0.045). Lower 25(OH)D concentrations were also associated with higher aPWV after adjusting for all the above-mentioned factors (model 3: ß = -0.241, p = 0.015). We conclude that both FGF-23 plasma concentrations (positively) and 25(OH)D serum concentrations (negatively) are associated with AS in patients with T1DM and no previous cardiovascular events.